DMACNasdaqPharmaceutical PreparationsFiscal year ends December 31
DiaMedica Therapeutics Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026
$7.87+0.30 (+3.96%)
Close on Oct 19, 2026
- Market cap
- $424.15M
- P/E (TTM)
- –
- Dividend yield
- –
DiaMedica Therapeutics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | DiaMedica Therapeutics | Industry median |
|---|---|---|
| Market Cap | $424.40M | $164.85M |
| Enterprise Value | $380.90M | $87.06M |
| PB Ratio | 11.07 | 2.03 |
| P/TBV Ratio | 11.07 | 2.31 |
Income (trailing twelve months)
| Measure | DiaMedica Therapeutics | Industry median |
|---|---|---|
| Operating Income | -$39.23M | -$21.44M |
| Pretax Income | -$37.51M | -$14.45M |
| Net Income | -$37.54M | -$22.46M |
| EBITDA | -$39.23M | -$16.91M |
| EPS (Diluted) | -$0.72 | -$0.83 |
Returns
| Measure | DiaMedica Therapeutics | Industry median |
|---|---|---|
| Return on Equity (ROE) | -114.6% | -53.1% |
| Return on Assets (ROA) | -98.2% | -41.0% |
| Return on Capital Employed (ROCE) | -102.1% | -37.8% |
Balance sheet
| Measure | DiaMedica Therapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $43.50M | $62.42M |
| Net Cash (Debt) | $43.50M | $15.68M |
| Net Cash Per Share | $0.81 | $0.66 |
| Equity (Book Value) | $38.34M | $48.79M |
| Book Value Per Share | $0.71 | $1.36 |
| Tangible Book Value | $38.34M | $23.06M |
| Working Capital | $37.72M | $75.77M |
Financial position
| Measure | DiaMedica Therapeutics | Industry median |
|---|---|---|
| Current Ratio | 6.72 | 3.30 |
| Quick Ratio | 6.63 | 2.39 |
Cash flow (trailing twelve months)
| Measure | DiaMedica Therapeutics | Industry median |
|---|---|---|
| Operating Cash Flow | -$31.51M | -$12.35M |
| Capital Expenditures | -$33.00K | -$1.06M |
| Free Cash Flow | -$31.54M | -$20.28M |
| FCF Per Share | -$0.58 | -$0.42 |
Efficiency
| Measure | DiaMedica Therapeutics | Industry median |
|---|---|---|
| Profits Per Employee | -$1.07M | -$703.34K |
| Employee Count | 35 | 74 |
Dividends and yields
| Measure | DiaMedica Therapeutics | Industry median |
|---|---|---|
| Earnings Yield | -8.85% | -22.7% |
| FCF Yield | -7.43% | -9.07% |
Shares
| Measure | DiaMedica Therapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 53,925,700 | 58,179,650 |
| Shares Change (YoY) | 22.4% | 11.1% |
| Shares Change (QoQ) | 0.08% | 0.54% |
| Float | 47,350,300 | 49,173,100 |
| Shares Held by Insiders | 12.2% | 11.6% |
| Shares Held by Institutions | 23.1% | 59.4% |
Taxes
| Measure | DiaMedica Therapeutics | Industry median |
|---|---|---|
| Income Tax | $30.00K | $91.50K |
Scores
| Measure | DiaMedica Therapeutics | Industry median |
|---|---|---|
| Altman Z-Score | 30.34 | -0.24 |
| Piotroski F-Score | 3 | 4 |
Calculated by StockData from DiaMedica Therapeutics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.